Pfizer, Lilly disclose ED ad schedules

Share this article:
Pfizer, Lilly disclose ED ad schedules
Pfizer, Lilly disclose ED ad schedules
Pfizer and Lilly shared their schedules for Viagra and Cialis TV ads with the Parents Television Council, which published them on its website so that parents bothered by the spots could shield their kids from them.

The group, which militates against sex, violence and profanity on television, said it began working with pharmas to address parents' concerns about erectile dysfunction (ED) drug ads two years ago, when a representative spoke at Lilly's annual meeting, and followed up in talks with Pfizer, Lilly and GlaxoSmithKline (which later discontinued advertising for its ED drug, Levitra).

“We applaud all three companies for their willingness to address the concerns raised by parents, grandparents and others who have been caught off guard by ED advertisements,” said the group's president, Tim Winter, in a statement.

Pharmas typically hold their media schedules close to their vests for competitive reasons.

TV ads for ED drugs have for years been a particular sore point with legislators and the public, and PhRMA has twice in the past five years issued rules for when and where companies can air them, seeking to blunt congressional momentum for restrictions on consumer advertising.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...